Skip to main content

For Professionals

For Professionals


Download transcript

Amitriptyline: A safe, effective, well-tolerated option for second-line management of Irritable Bowel Syndrome

The ATLANTIS trial recruited 463 patients with persistent IBS symptoms from general practices and found that low-dose amitriptyline was found to be superior to placebo in reducing IBS symptoms such as abdominal pain and bloating, and improved satisfaction with bowel habit. Low-dose amitriptyline was found to be safe and well tolerated in all IBS subtypes. Patients self-titrated their dosage according to symptoms. This new evidence reinforces the importance of discussing it with patients who haven’t responded to first-line therapies.


Trial Results

GP Results Summary (.pdf)


Useful Links